Farther Finance Advisors
TSHA icon

Farther Finance Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Farther Finance Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$365 Buy
75
+20
+36% +$115 ﹤0.01% 5799
2026
Q2 		$375 Hold
55
– – ﹤0.01% 5595
2026
Q1 		$237 Hold
55
– – ﹤0.01% 5400
2025
Q4 		$303 Hold
55
– – ﹤0.01% 5136
2025
Q3 		$180 Buy
+55
New +$156 ﹤0.01% 4742

Other funds holding TSHA

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $169M AUM 17.63% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Farther Finance Advisors's TSHA Position: Q3 2026 in Review

Farther Finance Advisors increased its Taysha Gene Therapies (TSHA) stake by 36% in Q3 2026, buying an estimated $115 and bringing the position to 75 shares worth $365. The position accounts for ﹤0.01% of the portfolio, ranked #5799.

Farther Finance Advisors first reported a position in TSHA in Q3 2025 and has held it in 5 quarters since. The position peaked at $375 in Q2 2026. 7 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.

  • Farther Finance Advisors held 75 shares of Taysha Gene Therapies worth $365 as of Q3 2026.
  • Farther Finance Advisors bought 20 Taysha Gene Therapies shares in Q3 2026, an estimated $115.
  • Taysha Gene Therapies made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5799 holding.
  • Farther Finance Advisors first reported a position in Taysha Gene Therapies in Q3 2025 and has held it in 5 quarters since.
  • Farther Finance Advisors's Taysha Gene Therapies position peaked at $375 in Q2 2026.
  • 7 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.